Related Experiment Video
Updated: Jan 23, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
Validity of an NGS-based multiple gene panel in identifying actionable mutations for patients with NSCLC in a Chinese
Wei Cao1, Chenghai Yan2, Hailong Wang2
1Department of Cardiothoracic Surgery, The Second Hospital of Anhui Medical University, Hefei, Anhui 230601, P.R. China.
Abstract:
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. A number of targeted therapies have been approved for clinical use or are in clinical trials. Next generation sequencing (NGS) is widely applied in the identification of actionable genomic alterations and enables personalized cancer therapy for patients. Several multiple-gene panels are available in China for the practice of precision medicine-based cancer therapy. However, the efficiency of these panels requires evaluation. The current study investigated 23 NSCLC samples using a custom designed panel of complete coding regions of ~180 cancer driver genes (FD-180) and whole exome sequencing for control samples, obtained from white blood cell samples. The results obtained suggested that actionable mutations with available targeted therapeutic options were identified in 69.6% of cases, including 60.9% of therapeutic targets recommended by the National Comprehensive Cancer Network guidelines. Furthermore, 8.7% of patients had a gene mutation that potentially qualified them for clinical trials or associated off-label therapies. As such, the results obtained in the current study demonstrated the reliability of the targeted NGS panel and its potential use for identifying actionable gene alterations and designing personalized therapies for patients with NSCLC.
Insights
A custom next-generation sequencing (NGS) panel identified actionable mutations in 69.6% of non-small cell lung cancer (NSCLC) patients, supporting its use for personalized therapy. This reliable targeted NGS panel aids in discovering gene alterations for tailored cancer treatments.
Area of Science:
- Oncology
- Genomics
- Molecular Diagnostics
Background:
- Non-small cell lung cancer (NSCLC) is the most prevalent form of lung cancer.
- Targeted therapies and precision medicine are increasingly important in NSCLC treatment.
- Multiple-gene panels are utilized in China for precision cancer therapy, necessitating efficiency evaluation.
Purpose of the Study:
- To evaluate the efficiency of a custom-designed targeted next-generation sequencing (NGS) panel for identifying actionable genomic alterations in NSCLC.
- To assess the reliability of the FD-180 panel in detecting mutations relevant to targeted therapies and clinical trials.
Main Methods:
- Investigated 23 NSCLC samples using a custom panel (FD-180) covering ~180 cancer driver genes.
- Utilized whole exome sequencing on white blood cell samples as controls.
- Analyzed identified mutations for actionable therapeutic options and clinical trial eligibility.
Main Results:
- Actionable mutations with available targeted therapies were found in 69.6% of NSCLC cases.
- Therapeutic targets recommended by National Comprehensive Cancer Network guidelines were identified in 60.9% of cases.
- Gene mutations qualifying patients for clinical trials or off-label therapies were present in 8.7% of patients.
Conclusions:
- The custom-designed targeted NGS panel (FD-180) demonstrates reliability for NSCLC.
- The panel effectively identifies actionable gene alterations for personalized cancer therapy.
- This approach supports the design of tailored treatment strategies for NSCLC patients.
Related Concept Videos
Mutation, Gene Flow, and Genetic Drift
Hospitals-II
Nurses that work in...
Hospitals-I
Mutations
Wood Panel Products
Viral Mutations

